In its second quarter ended July 3, 2026, Enovis demonstrated solid operational momentum driven by growth in both Prevention & Recovery and Reconstructive segments, supported by recent acquisitions and sustained product adoption. The company’s strategy to span the musculoskeletal care continuum—from bracing to implants—combined with surgeon education and innovative digital tools, reinforces its clinical differentiation against peers. Multi-channel distribution and geographic diversification, including approximately 42% international sales, provide resilience amidst competitive and regulatory pressures. While acquisition integration remains an execution risk, Enovis’s Enovis Growth Excellence system underpins operational discipline as it navigates leverage constraints amid ongoing investments in R&D and global market expansion.